Rep. Gilbert Ray Cisneros, Jr. Sells Insmed, Inc. (NASDAQ:INSM) Stock

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Insmed, Inc. (NASDAQ:INSM). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on October 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of CommVault Systems (NASDAQ:CVLT) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Cohen & Steers (NYSE:CNS) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of UFP Industries (NASDAQ:UFPI) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Enerpac Tool Group (NYSE:EPAC) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Iberdrola (OTCMKTS:IBDSF) on 10/21/2025.

Insmed Price Performance

Shares of NASDAQ INSM traded up $4.58 during mid-day trading on Monday, reaching $203.34. The company had a trading volume of 1,329,011 shares, compared to its average volume of 2,628,036. The company has a 50-day moving average price of $167.74 and a two-hundred day moving average price of $125.59. The stock has a market cap of $43.37 billion, a PE ratio of -35.61 and a beta of 1.05. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $208.00.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company’s revenue for the quarter was up 52.4% compared to the same quarter last year. During the same quarter last year, the business earned ($1.27) EPS. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 20th. UBS Group raised their price objective on shares of Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. William Blair started coverage on shares of Insmed in a research note on Wednesday, August 20th. They set an “outperform” rating on the stock. Cowen reaffirmed a “buy” rating on shares of Insmed in a research report on Thursday. Finally, Truist Financial upped their price target on Insmed from $126.00 to $139.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.53.

Insider Activity at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the sale, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This represents a 67.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the completion of the transaction, the director owned 262,675 shares in the company, valued at $38,190,318.25. This trade represents a 3.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 252,922 shares of company stock valued at $43,533,383 over the last ninety days. Insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Hedge funds have recently made changes to their positions in the company. Mutual of America Capital Management LLC raised its holdings in Insmed by 2.7% in the 1st quarter. Mutual of America Capital Management LLC now owns 79,141 shares of the biopharmaceutical company’s stock valued at $6,038,000 after buying an additional 2,093 shares during the last quarter. CWM LLC increased its holdings in Insmed by 24.5% in the first quarter. CWM LLC now owns 2,052 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 404 shares during the period. Signaturefd LLC raised its position in Insmed by 60.0% during the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 325 shares during the last quarter. Cullen Frost Bankers Inc. lifted its holdings in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares during the period. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in shares of Insmed in the 1st quarter valued at about $975,000.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.